Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 13:2021:9940169.
doi: 10.1155/2021/9940169. eCollection 2021.

Therapeutic Potential of Polyphenols in the Management of Diabetic Neuropathy

Md Tanvir Kabir  1 , Nuzhat Tabassum  2 , Md Sahab Uddin  3   4 , Faissal Aziz  5   6 , Tapan Behl  7 , Bijo Mathew  8 , Md Habibur Rahman  3 , Raushanara Akter  1 , Abdur Rauf  9 , Lotfi Aleya  10
Affiliations
Review

Therapeutic Potential of Polyphenols in the Management of Diabetic Neuropathy

Md Tanvir Kabir et al. Evid Based Complement Alternat Med. .

Abstract

Diabetic neuropathy (DN) is a common and serious diabetes-associated complication that primarily takes place because of neuronal dysfunction in patients with diabetes. Use of current therapeutic agents in DN treatment is quite challenging because of their severe adverse effects. Therefore, there is an increased need of identifying new safe and effective therapeutic agents. DN complications are associated with poor glycemic control and metabolic imbalances, primarily oxidative stress (OS) and inflammation. Various mediators and signaling pathways such as glutamate pathway, activation of channels, trophic factors, inflammation, OS, advanced glycation end products, and polyol pathway have a significant contribution to the progression and pathogenesis of DN. It has been indicated that polyphenols have the potential to affect DN pathogenesis and could be used as potential alternative therapy. Several polyphenols including kolaviron, resveratrol, naringenin, quercetin, kaempferol, and curcumin have been administered in patients with DN. Furthermore, chlorogenic acid can provide protection against glutamate neurotoxicity via its hydrolysate, caffeoyl acid group, and caffeic acid through regulating the entry of calcium into neurons. Epigallocatechin-3-gallate treatment can protect motor neurons by regulating the glutamate level. It has been demonstrated that these polyphenols can be promising in combating DN-associated damaging pathways. In this article, we have summarized DN-associated metabolic pathways and clinical manifestations. Finally, we have also focused on the roles of polyphenols in the treatment of DN.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Diabetic neuropathy pathogenesis-associated metabolic pathways.
Figure 2
Figure 2
Chemical structures of various polyphenolic compounds that can be effective in the treatment of diabetic neuropathy.
Figure 3
Figure 3
Possible effects of polyphenols in the management of diabetic neuropathy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bril V. Treatments for diabetic neuropathy. Journal of the Peripheral Nervous System. 2012;17(2):22–27. doi: 10.1111/j.1529-8027.2012.00391.x. - DOI - PubMed
    1. Callaghan B. C., Cheng H. T., Stables C. L., Smith A. L., Feldman E. L. Diabetic neuropathy: clinical manifestations and current treatments. The Lancet Neurology. 2012;11(6):521–534. doi: 10.1016/S1474-4422(12)70065-0. - DOI - PMC - PubMed
    1. Tesfaye S., Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes/Metabolism Research and Reviews. 2012;28(1):8–14. doi: 10.1002/dmrr.2239. - DOI - PubMed
    1. Thomas P. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes. 1997;46(2):S54–S57. doi: 10.2337/diab.46.2.s54. - DOI - PubMed
    1. Boulton A. J. M., Vinik A. I., Arezzo J. C., et al. Diabetic neuropathies: a statement by the American diabetes association. Diabetes Care. 2005;28(4):956–962. doi: 10.2337/diacare.28.4.956. - DOI - PubMed